Eisai Plans EU, U.S. Applications For Epilepsy Drug Based On Trials
This article was originally published in PharmAsia News
Executive Summary
Eisai said that based on three Phase III studies, it would apply for marketing approval in the European Union and the United States for its epilepsy drug